CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech

BioNTech’s acquisition of CureVac will be implemented as planned

11-Aug-2025
AI-generated image

Symbolic image

CureVac N.V. announced that CureVac N.V. and an affiliate (together, “CureVac”), and an affiliate of GSK plc have entered into agreements with BioNTech SE and an affiliate (together, “BioNTech”) and Pfizer, Inc. to resolve and dismiss all pending patent litigation in the United States between the companies related to mRNA-based Covid-19 vaccines and to set a framework for resolving ongoing patent disputes outside the US upon closing of BioNTech’s acquisition of CureVac announced on June 12, 2025.

Under the terms of the agreements, CureVac and GSK will receive in aggregate a payment of $740 million as well as single-digit royalties on sales of COVID-19 vaccines in the United States going forward. Additionally, CureVac will receive $50 million from GSK for monetizing a portion of U.S. product royalties due under its existing license agreement announced on July 3, 2024.

Furthermore, as part of the settlement agreements, CureVac will grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import into the U.S. and sell mRNA-based COVID-19 and/or influenza products. Such non-exclusive license will be expanded into a worldwide license upon the closing of BioNTech’s acquisition of CureVac.

Subject to regulatory approval, BioNTech’s acquisition of CureVac as announced on June 12, 2025 will be implemented as planned and its terms will remain unaffected.

Other news from the department politics & laws

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Time out: We all need a three-day weekend - Researchers confirm health benefits

Time out: We all need a three-day weekend - Researchers confirm health benefits

Ibidi Awarded With the German bAV Prize 2023

Ibidi Awarded With the German bAV Prize 2023

Using AI as an exam tutor - Artificial intelligence is set to help human examinees study more effectively

Using AI as an exam tutor - Artificial intelligence is set to help human examinees study more effectively

EXIST start-up grant for virtual reality laboratory training - "Wet-Lab-VR": Virtual reality technology revolutionises training for molecular biology laboratories

EXIST start-up grant for virtual reality laboratory training - "Wet-Lab-VR": Virtual reality technology revolutionises training for molecular biology laboratories

2025 Future Insight Prize Awarded to Helmholtz Center’s Magdalena Götz for Breakthroughs in Brain Regeneration

2025 Future Insight Prize Awarded to Helmholtz Center’s Magdalena Götz for Breakthroughs in Brain Regeneration

Supervisory Board of Bayer AG extends contract of CEO Bill Anderson - Far-reaching transformation advancing, delivering first signs of success

Supervisory Board of Bayer AG extends contract of CEO Bill Anderson - Far-reaching transformation advancing, delivering first signs of success

VTU Group appoints Liam O'Neil as new CEO

VTU Group appoints Liam O'Neil as new CEO

Bayer extends partnership with Tsinghua University to accelerate pharmaceutical research in China - Extended collaboration underscores Bayer's commitment and growth strategy in innovation in China and globally

Bayer extends partnership with Tsinghua University to accelerate pharmaceutical research in China - Extended collaboration underscores Bayer's commitment and growth strategy in innovation in China and globally

Intelligent wound dressing controls inflammation - ETH start-up is developing a granular hydrogel that selectively captures inflammatory signals from chronic wounds while also actively promoting healing

Intelligent wound dressing controls inflammation - ETH start-up is developing a granular hydrogel that selectively captures inflammatory signals from chronic wounds while also actively promoting healing

Ready and running – WACKER Biotechnology Center in Munich - The focus will be on research in manufacturing processes for biopharmaceuticals and ingredients for food and dietary supplements

Ready and running – WACKER Biotechnology Center in Munich - The focus will be on research in manufacturing processes for biopharmaceuticals and ingredients for food and dietary supplements

Merck and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration - Strategic academic-industry alliance aims to build robust Research & Development talent pipeline

Merck and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration - Strategic academic-industry alliance aims to build robust Research & Development talent pipeline

WACKER and start-up Gearbox Biosciences announce strategic collaboration - The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA)

WACKER and start-up Gearbox Biosciences announce strategic collaboration - The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA)